clinical trial · NCT05114486
Safety & Efficacy of Pilocarpine Ophthalmic Spray for Temporary Improvement of Near Vision in Presbyopic Adults
Eyenovia Inc.·phase3·completed·n = 145
PresbyopiaPilocarpine Ophthalmic administered with the Optejet dispenserPlacebo administered with the Optejet dispenser
brief summary
Volunteer participants are evaluated for eligibility during a Screening Visit; those meeting study inclusion/exclusion criteria are scheduled for 2 treatment visits. At each treatment visit, 1 of the 2 study treatments is self-administered to both eyes. Afterwards, efficacy and safety assessments are performed over a 3-hour period.
started
Nov 3, 2021
primary completion
Sep 20, 2022
completion
Sep 20, 2022
last updated
Sep 11, 2023
official title
A Phase 3 Study of the Safety and Efficacy of 2% Pilocarpine Ophthalmic Spray Administered With the Optejet® Microdose Dispenser for Temporary Improvement of Near Vision in Adults With Presbyopia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol